Palatin Technologies (PTN) said Friday that topline results from its phase 2 study of PL8177 in patients with active ulcerative colitis showed clinical remission in 33% of treated patients after eight weeks of treatment, while none in the placebo group achieved remission.
Nine of the 12 patients received PL8177, and 78% of the treated group showed a clinical response, according to the company.
CEO Carl Spana said the strong data, along with prior findings, supports ongoing licensing discussions with multiple pharmaceutical companies.
Shares of Palatin were down 7.6% in recent trading.
Price: 0.65, Change: -0.05, Percent Change: -7.57
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.